Atlas Trials

Radiation and Durvalumab Immunotherapy As Neoadjuvant Treatment for MIBC

Clinical trial NCT04543110 · UNKNOWN

Trial details

NCT number
NCT04543110
Sponsor
Ottawa Hospital Research Institute
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Bladder Cancer
Start date
2021-01-29
Primary completion
2023-10-01
Enrollment
16

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.